Frequency Therapeutics Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
David Lucchino
Chief executive officer
US$3.2m
Total compensation
| CEO salary percentage | 19.9% |
| CEO tenure | 9yrs |
| CEO ownership | 1.7% |
| Management average tenure | no data |
| Board average tenure | 7.2yrs |
Recent management updates
Recent updates
Is Frequency Therapeutics (NASDAQ:FREQ) Weighed On By Its Debt Load?
Jan 01
Frequency Therapeutics (NASDAQ:FREQ) Has Debt But No Earnings; Should You Worry?
Jan 19Frequency Therapeutics, Inc. (NASDAQ:FREQ) Analysts Are Reducing Their Forecasts For This Year
Aug 18Health Check: How Prudently Does Frequency Therapeutics (NASDAQ:FREQ) Use Debt?
Jul 31Frequency Therapeutics (FREQ) Investor Presentation - Slideshow
Jun 18Frequency Therapeutics: A Look At What's Next After A Disappointing Data Readout
Apr 21Frequency Therapeutics, Inc. (NASDAQ:FREQ) Analysts Are More Bearish Than They Used To Be
Apr 04We're Not Worried About Frequency Therapeutics' (NASDAQ:FREQ) Cash Burn
Mar 15If You Had Bought Frequency Therapeutics (NASDAQ:FREQ) Shares A Year Ago You'd Have Earned 55% Returns
Jan 22Have Insiders Sold Frequency Therapeutics, Inc. (NASDAQ:FREQ) Shares Recently?
Dec 27Frequency Therapeutics to host investor event in early January next year
Dec 18How Much Are Frequency Therapeutics, Inc. (NASDAQ:FREQ) Insiders Taking Off The Table?
Dec 10Frequency Therapeutics, Inc. (NASDAQ:FREQ) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Nov 19Frequency Therapeutics EPS beats by $0.16, beats on revenue
Nov 16Frequency Therapeutics Is An Interesting Speculative Play Ahead Of Phase 2 Results
Nov 09CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2023 | n/a | n/a | -US$59m |
| Jun 30 2023 | n/a | n/a | -US$67m |
| Mar 31 2023 | n/a | n/a | -US$78m |
| Dec 31 2022 | US$3m | US$630k | -US$82m |
| Sep 30 2022 | n/a | n/a | -US$86m |
| Jun 30 2022 | n/a | n/a | -US$91m |
| Mar 31 2022 | n/a | n/a | -US$88m |
| Dec 31 2021 | US$6m | US$600k | -US$85m |
| Sep 30 2021 | n/a | n/a | -US$73m |
| Jun 30 2021 | n/a | n/a | -US$54m |
| Mar 31 2021 | n/a | n/a | -US$42m |
| Dec 31 2020 | US$5m | US$551k | -US$27m |
| Sep 30 2020 | n/a | n/a | -US$22m |
| Jun 30 2020 | n/a | n/a | -US$18m |
| Mar 31 2020 | n/a | n/a | -US$19m |
| Dec 31 2019 | US$7m | US$442k | -US$20m |
| Sep 30 2019 | n/a | n/a | -US$20m |
| Jun 30 2019 | n/a | n/a | -US$23m |
| Mar 31 2019 | n/a | n/a | -US$21m |
| Dec 31 2018 | US$744k | US$367k | -US$19m |
Compensation vs Market: David's total compensation ($USD3.16M) is above average for companies of similar size in the US market ($USD2.23M).
Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.
CEO
David Lucchino (53 yo)
9yrs
Tenure
US$3,159,278
Compensation
Mr. David L. Lucchino is a Co-Founder of Frequency Therapeutics, Inc. and has been its Chief Executive Officer and President since November 2014. Mr. Lucchino served as Treasurer and Secretary of Frequency...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 9yrs | US$3.16m | 1.73% $ 9.5m | |
| Senior Advisor & Member of PCA Regenerative Medicine Advisory Board | 6.7yrs | no data | no data | |
| Independent Vice Chairman | 7.2yrs | US$104.32k | 0.22% $ 1.2m | |
| Independent Director & Member of PCA Regenerative Medicine Advisory Board | 7.2yrs | US$133.32k | 0.66% $ 3.6m | |
| Independent Director | 3.2yrs | US$92.82k | 0% $ 0 | |
| Member of PCA Regenerative Medicine Advisory Board | no data | no data | no data | |
| Member of PCA Regenerative Medicine Advisory Board | no data | no data | no data | |
| Member of PCA Regenerative Medicine Advisory Board | no data | no data | no data | |
| Member of PCA Regenerative Medicine Advisory Board | no data | no data | no data | |
| Member of PCA Regenerative Medicine Advisory Board | no data | no data | no data | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Member of Clinical Advisory Board | no data | no data | no data |
7.2yrs
Average Tenure
72.5yo
Average Age
Experienced Board: FREQ's board of directors are considered experienced (7.2 years average tenure).